Suven Life receives product patents in Israel and Japan

Gayathri Udyawar
/ Categories: Trending, Markets

Leading biopharma company, Suven Life Sciences Limited announced the grant of one product patent from Israel and one product patent from Japan new chemical compounds for the treatment of neurodegenerative diseases.

 

The issued claims of the patents are for class of selective M1 PAM and 5-HT4 compounds and are being developed as medications for the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Huntington’s disease, Parkinson , ADHD and schizophrenia.

 

The company's pipeline of molecules in the CNS therapeutic area have high unmet potential, internationally. Suven Life Science has four clinical stage compounds in various phases.

 

On Tuesday, the stock of Suven Life Sciences was trading Rs. 245.35 per share, up by 1.91 per cent on BSE, while the benchmark index was at 34,991.91, up by 40.99 points or 0.12 per cent.

Previous Article GIL reports another blockbuster quarter
Next Article Mutual fund Update: Two-third of retail MF investors stay invested beyond a year
Rate this article:
5.0

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

SEBI Registered Research Analyst Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INH000006396
Validity: Oct 05, 2018 - Perpetual

View Registration Certificate

SEBI Registered Investment Adviser Details:
Registered Name: DSIJ PRIVATE LIMITED
Type of registration: Non-Individual
Registration No.: INA000001142
Validity: Aug 19, 2019 - Perpetual

View Registration Certificate

Registered Address:
419-A, 4th floor, Arun Chambers,
Tardeo, Next to AC Market, Mumbai - 400 034.
Tel: +91 022-43476012/13/14/15 | Email: service@dsij.in
CIN No.: U22120MH2003PTC139276
GST No.: 27AACCR4303G1ZP
BASL Membership ID: 1346

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR

Disclaimer: "Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"

Investment in securities market is subject to market risks. Read all the related documents carefully before investing.

Any act of copying, reproducing, or distributing the content whether wholly or in part, for any purpose without the permission of DSIJ is strictly prohibited and shall be deemed to be copyright infringement.

Disclosures | Terms & Condition | Privacy Statement | WhiteList